FDA Tentative Approval Clears Path for Dr. Reddy’s Generic HIV PrEP at $40 Annual Cost

The approval targets a long-acting injectable PrEP formulation previously limited to branded pricing above $3,000 annually in high-income markets. Dr. Reddy’s plans initial distribution through global health partnerships that have pre-negotiated volume commitments, aiming to reach several million at-risk individuals in sub-Saharan Africa and Southeast Asia by 2027. This step follows earlier voluntary licensing agreements and reflects coordinated pressure from organizations tracking PrEP access gaps.

Lonza’s simultaneous acquisition of five Merck KGaA U.S. sites expands domestic capacity for complex biologics and gene therapies, indirectly supporting future generic injectable supply chains. The deal doubles Lonza’s U.S. footprint while Merck sharpens focus on development, illustrating how contract manufacturers are consolidating advanced manufacturing assets amid rising demand for long-acting antiretrovirals.

Prior coverage understated the regulatory distinction between tentative and full approval, which restricts U.S. sales until patent or exclusivity issues resolve. Real-world adherence data from observational cohorts in similar programs suggest annual injectable PrEP can achieve 60-75% persistence versus 40% for daily oral regimens, yet supply-chain bottlenecks and cold-chain requirements remain unaddressed risks.

Next milestones include full WHO prequalification and post-marketing surveillance for resistance emergence. Regulators will need at least two years of utilization data before considering broader label expansions or U.S. market entry.